Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose mRNA-1273 Booster for Lung Transplant Recipients
NCT05280158Phase 2Terminated
- Sponsor
- University of California, Los Angeles
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by University of California, Los Angeles. Started Mar 2022; status: terminated.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05280158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280158.